Regulation of tissue responses: The TWEAK/Fn14 pathway and other TNF/TNFR superfamily members that activate non-canonical NFκB signaling

Frontiers in Immunology

Volumn 6, Issue MAR, 2015, Pages

  Burkly, Linda C ^a  

^a BIOGEN   (United States)

Author keywords

Fn14; Non canonical NF B signaling; TNF superfamily; TNFR superfamily; TWEAK

Indexed keywords

BAFFR PROTEIN; CD40 ANTIGEN; FN14 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN BETA RECEPTOR; PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TWEAK PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; BLOOD BRAIN BARRIER; CARDIOVASCULAR DISEASE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DRUG TARGETING; EDITORIAL; FIBROSIS; HOMEOSTASIS; HUMAN; INFLAMMATION; INJURY; KIDNEY DISEASE; LEUKOCYTE; METABOLIC ACTIVATION; NEOPLASM; NEUROLOGIC DISEASE; PATHOGENESIS; PROTEIN SYNTHESIS REGULATION; SIGNAL TRANSDUCTION; STEM CELL; TISSUE REACTION; TISSUE REGENERATION; UBIQUITINATION; UPREGULATION;

EID: 84926656178     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00092     Document Type: Editorial

References (21)

1. Burkly LC. TWEAK/Fn14 axis: the current paradigm of tissue injury-inducible function in the midst of complexities. Semin Immunol (2014) 26:229. doi: 10.1016/j.smim.2014.02.006.
2. Cheng E, Armstrong CL, Galisteo R, Winkles JA. TWEAK/Fn14 axis-targeted therapeutics: moving basic science discoveries to the clinic. Front Immunol (2013) 4:473. doi:10.3389/fimmu.2013.00473.
3. Yepes M. TWEAK and Fn14 in the neurovascular unit. Front Immunol (2013) 4:367. doi:10.3389/fimmu.2013.00367.
4. Stock AD, Wen J, Putterman C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front Immunol (2013) 4:484. doi:10.3389/fimmu.2013.00484.
5. Poveda J, Tabara LC, Fernandez-Fernandez B, Martin-Cleary C, Sanz AB, Selgas R, et al. TWEAK/Fn14 and non-canonical NF-kappaB signaling in kidney disease. Front Immunol (2013) 4:447. doi:10.3389/fimmu.2013.00447.
6. Blanco-Colio LM. TWEAK/Fn14 axis: a promising target for the treatment of cardiovascular diseases. Front Immunol (2014) 5:3. doi:10.3389/fimmu.2014.00003.
7. Vendrell J, Chacon M. TWEAK: a new player in obesity and diabetes. Front Immunol (2013) 4:488. doi:10.3389/fimmu.2013.00488.
8. Novoyatleva T, Sajjad A, Engel FB. TWEAK-Fn14 cytokine-receptor axis: a new player of myocardial remodeling and cardiac failure. Front Immunol (2014) 5:50. doi:10.3389/fimmu.2014.00050.
9. Bertin D, Stephan D, Khrestchatisky M, Desplat-Jégo S. Is TWEAK a biomarker for autoimmune/chronic inflammatory diseases? Front Immunol (2013) 4:489. doi:10.3389/fimmu.2013.00489.
10. Sato S, Ogura Y, Kumar A. TWEAK/Fn14 signaling axis mediates skeletal muscle atrophy and metabolic dysfunction. Front Immunol (2014) 5:18. doi:10.3389/fimmu.2014.00018.
11. Enwere EK, Lacasse EC, Adam NJ, Korneluk RG. Role of the TWEAK-Fn14-cIAP1-NF-kB signaling axis in the regulation of myogenesis and muscle homeostasis. Front Immunol (2014) 5:34. doi:10.3389/fimmu.2014.00034.
12. Purcell JW, Kim HK, Tanlimco SG, Doan M, Fox M, Lambert P, et al. Nuclear factor ?B is required for tumor growth inhibition mediated by enavatuzumab (PDL192), a humanized monoclonal antibody to TweakR. Front Immunol (2014) 4:505. doi:10.3389/fimmu.2013.00505.
13. Arana JAC, Seher A, Neumann M, Lang I, Siegmund D, Wajant H. TNF receptor associated factor 1 (TRAF1) is a major target of soluble TWEAK. Front Immunol (2014) 5:63. doi:10.3389/fimmu.2014.00063.
14. Vucic D. The role of ubiquitination in TWEAK stimulated signaling. Front Immunol (2013) 4:472. doi:10.3389/fimmu.2013.00472.
15. Faustman DL, Davis M. TNF receptor 2 and disease: autoimmunity and regenerative medicine. Front Immunol (2013) 4:478. doi:10.3389/fimmu.2013.00478.
16. Gardam S, Brink R. Non-canonical NF-κB signalling initiated by BAFF influences B cell biology at multiple junctures. Front Immunol (2014) 4:509. doi:10.3389/fimmu.2013.00509.
17. Hostager BS, Bishop GA. CD40-mediated activation of the NF-kB2 pathway. Front Immunol (2013) 4:376. doi:10.3389/fimmu.2013.00376.
18. Lin WW, Hildebrand JM, Bishop GA. A complex relationship between TRAF3 and non-canonical NF-κB2 activation in B lymphocytes. Front Immunol (2013) 4:477. doi:10.3389/fimmu.2013.00477.
19. Lu TT, Browning JL. Role of the lymphotoxin/LIGHT system in the development and maintenance of reticular networks and vasculature in lymphoid tissues. Front Immunol (2014) 5:47. doi:10.3389/fimmu.2014.00047.
20. Dwyer BJ, Olynyk JK, Ramm GA, Tirnitz-Parker JEE. TWEAK and LTβ signaling during chronic liver disease. Front Immunol (2014) 5:39. doi:10.3389/fimmu.2014.00039.
21. Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG system. Front Immunol (2014) 5:511. doi:10.3389/fimmu.2014.00511.